• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

AppliedVR Releases Clinical Trial Results from In-Home Virtual Reality Program for Chronic Lower Back Pain

by Fred Pennic 11/08/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– AppliedVR, an immersive therapeutics pioneer, conducted a large randomized controlled trial (RCT) on virtual reality (VR) therapy for treating chronic low back pain (CLBP) at home.

– Results of the study were published in Mayo Clinic Proceedings: Digital Health and demonstrated that AppliedVR’s RelieVRx program produced clinically meaningful improvements in adults with CLBP.

– AppliedVR aims to provide a non-pharmacological and non-invasive approach to treating chronic pain, with potential for long-lasting effects.

The RelieVRx Program Study and Results

The study included data from over 1,000 participants, with approximately half undergoing treatment with the RelieVRx program over eight weeks. Participants completing the RelieVRx program experienced an average reduction of 2.0 points in pain intensity on a numerical rating scale from zero to 10, along with a 2.3-point reduction in pain interference.

The RelieVRx program is a self-administered behavioral skills VR program authorized by the FDA for treating CLBP, incorporating principles of cognitive behavioral therapy, diaphragmatic breathing, biofeedback, cognition and emotion regulation, mindfulness, and pain education. Each chapter of interactive VR therapy builds upon the last to induce neuroplasticity, regulating neural regions associated with pain for long-lasting change. In previous clinical research, the RelieVRx program was shown to deliver durable effects up to 24 months after treatment completion.

Impact of Chronic Pain

The study aligns with AppliedVR’s efforts to secure reimbursement through CMS and expand access to its VR therapy for veterans through VA sites. Chronic pain is a significant healthcare concern with substantial economic and societal costs in the United States. Research has suggested that more than 72 million Americans suffer from chronic low back pain, with the condition being a leading cause of disability.”

“Pain is a complex condition that requires a multidisciplinary treatment approach. However, traditional clinical guidelines have over-relied on medications or surgical procedures, which can be costly and ineffective over the long term,” said Dr. Beth Darnall, AppliedVR chief science advisor, who co-authored the study. “This landmark study builds on our previous research at a much larger scale and demonstrates that RelieVRx can be a powerful tool in providers’ tool belts for treating people experiencing chronic low back pain.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AppliedVR, Immersive Virtual Reality, Therapeutic Virtual Reality, Virtual Reality

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |